Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Ultimovacs

DB:7UM
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
7UM
DB
NOK1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The last earnings update was 8 days ago. More info.


Add to Portfolio Compare Print
  • Ultimovacs has significant price volatility in the past 3 months.
7UM Share Price and Events
7 Day Returns
-9.5%
DB:7UM
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-
DB:7UM
-7.4%
DE Biotechs
-14.2%
DE Market
7UM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ultimovacs (7UM) -9.5% -28.7% -46.7% - - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • No trading data on 7UM.
  • No trading data on 7UM.
Price Volatility
Industry
5yr Volatility vs Market

7UM Value

 Is Ultimovacs undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Ultimovacs. This is due to cash flow or dividend data being unavailable. The share price is €2.58.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ultimovacs's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ultimovacs's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:7UM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in NOK NOK-2.67
OB:ULTIMO Share Price ** OB (2020-04-06) in NOK NOK39.5
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ultimovacs.

DB:7UM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OB:ULTIMO Share Price ÷ EPS (both in NOK)

= 39.5 ÷ -2.67

-14.81x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ultimovacs is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Ultimovacs is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Ultimovacs's expected growth come at a high price?
Raw Data
DB:7UM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -14.81x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-17.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Ultimovacs, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Ultimovacs's assets?
Raw Data
DB:7UM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in NOK NOK15.96
OB:ULTIMO Share Price * OB (2020-04-06) in NOK NOK39.5
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:7UM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OB:ULTIMO Share Price ÷ Book Value per Share (both in NOK)

= 39.5 ÷ 15.96

2.48x

* Primary Listing of Ultimovacs.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ultimovacs is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Ultimovacs's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Ultimovacs has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

7UM Future Performance

 How is Ultimovacs expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-17.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ultimovacs expected to grow at an attractive rate?
  • Unable to compare Ultimovacs's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Ultimovacs's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Ultimovacs's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:7UM Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:7UM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -17.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:7UM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in NOK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:7UM Future Estimates Data
Date (Data in NOK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 0 -120 -122 1
2021-12-31 0 -169 -171 1
2020-12-31 0 -138 -141 1
2020-04-09
DB:7UM Past Financials Data
Date (Data in NOK Millions) Revenue Cash Flow Net Income *
2019-12-31 -63 -61
2019-09-30 -59 -48
2019-06-30 -56 -48
2019-03-31 -54 -54
2018-12-31 -50 -55
2018-09-30 -45 -50
2018-06-30 -38 -42
2018-03-31 -32 -35
2017-12-31 -27 -33

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Ultimovacs is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Ultimovacs is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:7UM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Ultimovacs Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7UM Future Estimates Data
Date (Data in NOK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 -4.38 -4.38 -4.38 1.00
2021-12-31 -6.14 -6.14 -6.14 1.00
2020-12-31 -5.06 -5.06 -5.06 1.00
2020-04-09
DB:7UM Past Financials Data
Date (Data in NOK Millions) EPS *
2019-12-31 -2.67
2019-09-30 -2.43
2019-06-30 -2.83
2019-03-31 -3.29
2018-12-31 -3.55
2018-09-30 -3.31
2018-06-30 -2.91
2018-03-31 -2.54
2017-12-31 -2.49

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Ultimovacs will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Ultimovacs's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ultimovacs has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

7UM Past Performance

  How has Ultimovacs performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ultimovacs's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ultimovacs does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Ultimovacs's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Ultimovacs's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Ultimovacs's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ultimovacs Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7UM Past Revenue, Cash Flow and Net Income Data
Date (Data in NOK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -61.17 16.62
2019-09-30 -48.50 15.98
2019-06-30 -48.16 17.08
2019-03-31 -53.65 20.17
2018-12-31 -55.28 24.16
2018-09-30 -50.21 22.61
2018-06-30 -41.73 18.32
2018-03-31 -34.94 17.41
2017-12-31 -32.83 17.02
2016-12-31 -28.98 13.22

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Ultimovacs has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Ultimovacs has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Ultimovacs improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Ultimovacs's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ultimovacs has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

7UM Health

 How is Ultimovacs's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ultimovacs's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ultimovacs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ultimovacs's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ultimovacs's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are -9.1785837385606E+17x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ultimovacs Company Filings, last reported 3 months ago.

DB:7UM Past Debt and Equity Data
Date (Data in NOK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 444.63 0.00 399.61
2019-09-30 467.21 0.00 412.03
2019-06-30 485.02 0.00 446.04
2019-03-31 485.02 0.00 446.04
2018-12-31 159.90 0.00 115.54
2018-09-30 169.77 0.00 123.73
2018-06-30 140.80 0.00 144.14
2018-03-31 155.56 0.00 157.76
2017-12-31 166.48 0.00 169.81
2016-12-31 75.82 0.00 73.00
  • Ultimovacs's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Ultimovacs's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Ultimovacs has sufficient cash runway for more than 3 years based on current free cash flow.
  • Ultimovacs has sufficient cash runway for 2.9 years if free cash flow continues to grow at historical rates of 28.5% each year.
X
Financial health checks
We assess Ultimovacs's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ultimovacs has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

7UM Dividends

 What is Ultimovacs's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ultimovacs dividends.
If you bought €2,000 of Ultimovacs shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ultimovacs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ultimovacs's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:7UM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:7UM Future Dividends Estimate Data
Date (Data in NOK) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ultimovacs has not reported any payouts.
  • Unable to verify if Ultimovacs's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ultimovacs's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ultimovacs has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Ultimovacs's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ultimovacs afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ultimovacs has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

7UM Management

 What is the CEO of Ultimovacs's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Øyvind Arnesen
COMPENSATION NOK26,990,000
TENURE AS CEO 7.7 years
CEO Bio

Dr. Øyvind Kongstun Arnesen, MD, serves as Chief Executive Officer at Ultimovacs AS since August 2012. Dr. Arnesen is experienced within the pharmaceutical industry including positions as Medical Director and Head of Clinical Operations Nordic at Boehringer Ingelheim (Norway) from 2007 until 2012, Medical Director at Bristol-Myers Squibb (Norway) from 2004 until 2007 and Clinical Trial Manager at AstraZeneca AS from 1995 until 1996. Dr. Arnesen holds a Medical Doctor (MD) from the University of Oslo, Norway. Current Directorships and senior management positions: • The Norwegian Pharmaceutical Product Compendium, Board Member • Oslo Cancer Cluster, Board Member (Chairman) • Vitmed AS, CEO and Board Member. Previous Directorships and senior management positions in last five years: • Nedre Bygdølund Sameie, Alternate Board Member • The Norwegian Pharmaceutical Industry Association, Board member.

CEO Compensation
  • Øyvind's compensation has increased whilst company is loss making.
  • Øyvind's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Ultimovacs management team in years:

3.8
Average Tenure
  • The tenure for the Ultimovacs management team is about average.
Management Team

Øyvind Arnesen

TITLE
Chief Executive Officer
COMPENSATION
NOK27M
TENURE
7.7 yrs

Hans Eid

TITLE
Chief Financial Officer
TENURE
4.4 yrs

Audun Tornes

TITLE
Chief Operating Officer
TENURE
6.3 yrs

Ingunn Westgaard

TITLE
Head of Research

Wenche Rasch

TITLE
Head of International Clinical Development

Jens Egil Bjørheim

TITLE
Chief Medical Officer
TENURE
3.8 yrs

Øivind Foss

TITLE
Head of Clinical Operations
TENURE
2.7 yrs

Sara Mangsbo

TITLE
Chief Development Officer
TENURE
1.3 yrs

Gunilla Ekström

TITLE
Managing Director Ultimovacs AB
AGE
61

Gudrun Trøite

TITLE
Director of Regulatory Affairs & QA
TENURE
2.7 yrs
Board of Directors Tenure

Average tenure and age of the Ultimovacs board of directors in years:

4.8
Average Tenure
59
Average Age
  • The tenure for the Ultimovacs board of directors is about average.
Board of Directors

Jónas Einarsson

TITLE
Chairman
COMPENSATION
NOK1M
AGE
61
TENURE
9.3 yrs

Kristin Louise Wilhelmsen

TITLE
Director
COMPENSATION
NOK1M
AGE
57
TENURE
4.3 yrs

Leiv Askvig

TITLE
Director
COMPENSATION
NOK1M
AGE
62
TENURE
5.3 yrs

Henrik Schüssler

TITLE
Director
COMPENSATION
NOK1M
AGE
56
TENURE
5.3 yrs

Ketil Fjerdingen

TITLE
Director
COMPENSATION
NOK3M
TENURE
8.3 yrs

Eva Dugstad

TITLE
Director
TENURE
1.3 yrs

Kari Grønås

TITLE
Director
TENURE
1.3 yrs

Håkan Englund

TITLE
Board Observer
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Ultimovacs's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ultimovacs has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

7UM News

Simply Wall St News

7UM Company Info

Description

Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was founded in 2011 and is headquartered in Oslo, Norway.

Details
Name: Ultimovacs ASA
7UM
Exchange: DB
Founded: 2011
NOK98,636,423
27,860,400
Website: http://www.ultimovacs.com
Address: Ultimovacs ASA
Ullernchausséen 64,
Oslo,
Oslo, 0379,
Norway
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OB ULTIMO Ordinary Shares Oslo Bors NO NOK 03. Jun 2019
DB 7UM Ordinary Shares Deutsche Boerse AG DE EUR 03. Jun 2019
Number of employees
Current staff
Staff numbers
17
Ultimovacs employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 02:24
End of day share price update: 2020/04/06 00:00
Last estimates confirmation: 2020/02/17
Last earnings filing: 2020/04/01
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.